• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

    0.6893 -0.0507 (-6.85%)
    Delayed Quote Updated: 9:58 AM EDT, Oct 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 757,034
    Open 0.7400
    Bid (Size) 0.6805 (600)
    Ask (Size) 0.6981 (100)
    Prev. Close 0.7400
    Today's Range 0.6501 - 0.7400
    52wk Range 0.7254 - 5.930
    Shares Outstanding 58,576,350
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease ↗
    Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter... 
    Via MarketBeat

    Performance

    52-Week Range 88.4% below 52-week high
    0.6893
    0.7352W Low 5.9352W High
    1 Week 28.9% below 1-week high
    0.731W Low 0.971W High

    Aldeyra Therapeutics, Inc. - Common Stock (ALDX) traded between $0.73 and $5.93 over the past 52 weeks and last traded at $0.69, 88.4% below its 52-week high. Over the past week it ranged between $0.73 and $0.97.

    Past 12 Months
    -24.8%
    -49.7%
    -59.9%
    -61.7%
    -85.2%
    -87.8%
    1W -$0.23
    1M -$0.68
    3M -$1.03
    6M -$1.11
    YTD -$3.98
    1Y -$4.97

    ALDX was -87.8% over the past year, -61.7% over six months, -85.2% year to date, -24.8% in the last week.

    12 Months vs Market
    ALDX
    -87.8%
    DIA
    +13.4%
    SPY
    +16.0%
    QQQ
    +19.7%
    IWM
    +9.9%

    Over the past 12 months ALDX returned -87.8% versus DIA (Dow) +13.4%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +19.7% and IWM (Russell 2000) +9.9%.

    Volume & Liquidity 0.64× 3-mo avg
    Today 757,034 3-mo avg 1.2M
    1W
    1.3M
    1M
    1.8M
    3M
    1.2M
    6M
    1.3M
    YTD
    1.8M
    1Y
    1.6M

    ALDX most recently traded 757,034 shares against a 3-month average daily volume of 1.2M.

    More News

    Read More
    News headline image
    Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics to Host Regulatory Update Webcast
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    These stocks are gapping in today's session ↗
    Via Chartmill
    Which stocks are moving after the closing bell on Friday? ↗
    Via Chartmill
    News headline image
    Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment ↗
    Via MarketBeat
    News headline image
    Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    News headline image
    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
    From The Rosen Law Firm PA
    Via GlobeNewswire

    Frequently Asked Questions

    Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?
    Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?
    The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market
    What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?
    The current price of Aldeyra Therapeutics, Inc. - Common Stock is 0.6893
    When was Aldeyra Therapeutics, Inc. - Common Stock last traded?
    The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 10/16/26 09:58 AM ET
    What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?
    The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 40.38M
    How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?
    Aldeyra Therapeutics, Inc. - Common Stock has 40M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.